Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for genetically defined diseases. Founded in 2013, the company has made significant strides in the field of precision medicine, particularly in the development of its proprietary platform, the "BD2" technology, which enables the creation of highly selective medicines. With a strong emphasis on neurology and oncology, Black Diamond Therapeutics is committed to addressing unmet medical needs through its unique approach to drug discovery. The company has garnered attention for its promising pipeline of product candidates, including therapies targeting rare genetic disorders. Recognised for its advancements in the biotechnology sector, Black Diamond Therapeutics continues to solidify its position as a leader in the development of transformative treatments.
DitchCarbon Score
How does Black Diamond Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Black Diamond Therapeutics, Inc.'s score of 18 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Black Diamond Therapeutics, Inc.'s reported carbon emissions
Black Diamond Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As of now, there are no documented initiatives or commitments related to climate action or emissions reduction. In the absence of specific emissions figures, it is important to note that many companies in the biotechnology sector are increasingly focusing on sustainability and reducing their carbon footprints. Black Diamond Therapeutics may be expected to align with industry standards in the future, potentially adopting climate commitments or reduction strategies as part of a broader trend towards environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Black Diamond Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
